ArticleAdvances in radiation oncology2025
Predicting Radionecrosis After Stereotactic Radiation Therapy for Solitary Brain Metastases: External Validation of a Univariable Model and Development of a Multivariable Model.
Article in Advances in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Outcomes in long-term survivors treated with stereotactic cranial radiotherapy for brain metastases.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Stereotactic radiation therapy (SRT) is a frequently used and effective treatment for patients who received diagnosis for brain metastases (BMs). Radionecrosis (RN) is a severe complication of SRT which may cause neurologic symptoms. A normal tissue complication probability (NTCP) model has previously been established to predict the risk of RN based on the volume of healthy brain receiving ≥12 Gy. The aim of this study is to externally validate this prediction model. Methods and Materials: A total of 162 patients treated with SRT for solitary BMs were retrospectively included. The NTCP models for all (asymptomatic and symptomatic) RN and symptomatic RN cases were evaluated using discrimination (C-statistic) and calibration (Brier scores). Overall survival was determined using the Kaplan-Meier method. Results: Median overall survival was 10 months. Asymptomatic or symptomatic RN was found in 44 (27%) of patients. Of these, 26 (16%) RN cases were symptomatic, with actuarial rates of 11% and 22% after 6 and 12 months, respectively. The C-statistics of the "any RN" and the "symptomatic RN" models were identical (0.61). Brier scores were 0.201 and 0.217, respectively. Univariable logistic regression analysis showed a significant correlation between both tumor volume and volume of healthy brain receiving ≥12 Gy with symptomatic RN. These effects did not hold up in the multivariable analysis. A nomogram was established and internally validated. Conclusions: The accuracy of the tested NTCP models in assessing the risk of RN in patients with BM after SRT was insufficient for clinical practice. A novel multifactorial nomogram was developed to predict symptomatic RN. This model needs to be externally validated.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.